

Stuart Rich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10583289/publications.pdf>

Version: 2024-02-01

98
papers

22,043
citations

23500

58
h-index

37111

96
g-index

100
all docs

100
docs citations

100
times ranked

8265
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301.	13.9	2,529
2	Primary Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1987, 107, 216.	2.0	1,811
3	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S5-S12.	1.2	1,542
4	The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1992, 327, 76-81.	13.9	1,469
5	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 800-804.	2.5	1,288
6	Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 335, 609-616.	13.9	1,127
7	Survival in Primary Pulmonary Hypertension. <i>Circulation</i> , 2002, 106, 1477-1482.	1.6	1,092
8	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425.	2.0	905
9	Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1998, 338, 273-277.	13.9	639
10	Beraprost therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2119-2125.	1.2	563
11	Ultrafast Computed Tomography as a Diagnostic Modality in the Detection of Coronary Artery Disease. <i>Circulation</i> , 1996, 93, 898-904.	1.6	434
12	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D51-D59.	1.2	432
13	Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. <i>American Journal of Cardiology</i> , 2001, 87, 1335-1339.	0.7	401
14	Primary Pulmonary Hypertension. <i>Circulation</i> , 2000, 102, 2781-2791.	1.6	340
15	Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary Hypertension. <i>Chest</i> , 2011, 139, 988-993.	0.4	328
16	The Short-term Effects of Digoxin in Patients With Right Ventricular Dysfunction From Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 787-792.	0.4	322
17	Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1 α -Kv1.5 O ₂ -sensing pathway at the intersection of pulmonary hypertension and cancer. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H570-H578.	1.5	319
18	Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1581-1585.	1.2	281

#	ARTICLE	IF	CITATIONS
19	Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. <i>Circulation</i> , 1997, 95, 1479-1486.	1.6	271
20	Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 257-265.	1.6	253
21	Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults. <i>Chest</i> , 2014, 146, 449-475.	0.4	237
22	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Chest</i> , 2004, 126, 420-427.	0.4	232
23	Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 293-299.	0.8	219
24	Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2002, 121, 1860-1868.	0.4	214
25	Endothelin Receptor Blockers in Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 2184-2190.	1.6	205
26	Anorexigens and Pulmonary Hypertension in the United States. <i>Chest</i> , 2000, 117, 870-874.	0.4	183
27	The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1623-1630.	2.9	177
28	Doppler echocardiography assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1986, 8, 1298-1306.	1.2	175
29	The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1184-1187.	1.2	175
30	Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 668-674.	0.3	157
31	Pressure and Volume Loading of the Right Ventricle Have Opposite Effects on Left Ventricular Ejection Fraction. <i>Circulation</i> , 1995, 92, 819-824.	1.6	146
32	Primary pulmonary hypertension. <i>Progress in Cardiovascular Diseases</i> , 1988, 31, 205-238.	1.6	142
33	Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. <i>Journal of the American College of Cardiology</i> , 1992, 19, 84-90.	1.2	137
34	Reproducibility of the measurement of coronary calcium with ultrafast computed tomography. <i>American Journal of Cardiology</i> , 1995, 75, 973-975.	0.7	136
35	Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2006, 113, 2509-2515.	1.6	136
36	Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1985, 55, 159-163.	0.7	125

#	ARTICLE	IF	CITATIONS
37	Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 2475-2483.	1.6	116
38	Autoantibodies in patients with primary pulmonary hypertension: Association with anti-Ku. <i>American Journal of Medicine</i> , 1992, 93, 307-312.	0.6	112
39	Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2010, 138, 1234-1239.	0.4	109
40	Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. <i>American Journal of Medicine</i> , 1984, 76, 573-578.	0.6	108
41	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. <i>American Heart Journal</i> , 2010, 159, 245-257.	1.2	106
42	Clinical Diagnosis of Pulmonary Hypertension. <i>Circulation</i> , 2014, 130, 1820-1830.	1.6	100
43	Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension. <i>Circulation</i> , 2008, 118, 2190-2199.	1.6	95
44	Usefulness of Atrial Septostomy as a Treatment for Primary Pulmonary Hypertension and Guidelines for its Application. <i>American Journal of Cardiology</i> , 1997, 80, 369-371.	0.7	94
45	Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1992, 19, 1060-1064.	1.2	90
46	Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 1195-1201.	1.6	90
47	Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary Hypertension. <i>Chest</i> , 1995, 107, 54-57.	0.4	88
48	Efficacy and Safety of Sildenafil Added to Treprostinil in Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2005, 96, 1334-1336.	0.7	88
49	High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing. <i>Journal of the American College of Cardiology</i> , 1991, 18, 1323-1327.	1.2	84
50	The Current Treatment of Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 130, 1198-1202.	0.4	83
51	The Effects of Phenylephrine on Right Ventricular Performance in Patients with Pulmonary Hypertension. <i>Chest</i> , 1990, 98, 1102-1106.	0.4	80
52	Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1995, 75, 374-377.	0.7	78
53	Temporal trends and drug exposures in pulmonary hypertension: An American experience. <i>American Heart Journal</i> , 2006, 152, 521-526.	1.2	78
54	Primary Pulmonary Hypertension: Radiographic and Scintigraphic Patterns of Histologic Subtypes. <i>Annals of Internal Medicine</i> , 1986, 105, 499.	2.0	75

#	ARTICLE	IF	CITATIONS
55	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 131, 401-409.	1.6	72
56	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 464-475.	2.5	69
57	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. <i>American Heart Journal</i> , 2002, 143, 4A-10A.	1.2	68
58	Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 181-187.	0.3	62
59	Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 86-94.	0.5	61
60	Stenting To Reverse Left Ventricular Ischemia Due To Left Main Coronary Artery Compression in Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 1412-1415.	0.4	60
61	Noninvasive cardiac output measurements in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 42, 125-133.	3.1	59
62	The Prevalence and Significance of a Patent Foramen Ovale in Pulmonary Hypertension. <i>Chest</i> , 1993, 104, 1673-1675.	0.4	57
63	Clinical Insights Into the Pathogenesis of Primary Pulmonary Hypertension. <i>Chest</i> , 1998, 114, 237S-241S.	0.4	47
64	Right Ventricular Adaptation and Maladaptation in Chronic Pulmonary Arterial Hypertension. <i>Cardiology Clinics</i> , 2012, 30, 257-269.	0.9	44
65	Electron Beam Computed Tomography for Assessment of Coronary Artery Disease in HIV-Infected Men Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 191-195.	0.9	42
66	Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension. <i>Chest</i> , 2009, 136, 694-700.	0.4	42
67	Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 1993, 21, 413-418.	1.2	38
68	Medical treatment of primary pulmonary hypertension: A bridge to transplantation?. <i>American Journal of Cardiology</i> , 1995, 75, 63A-66A.	0.7	38
69	Successful management of labor and delivery in primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1993, 71, 1124-1125.	0.7	35
70	Detection of Subclinical Cardiovascular Disease: The Emerging Role of Electron Beam Computed Tomography. <i>Preventive Medicine</i> , 2002, 34, 1-10.	1.6	34
71	The 6-Minute Walk Test as a Primary Endpoint in Clinical Trials for Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1202-1203.	1.2	34
72	Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. <i>Histopathology</i> , 2012, 61, 597-609.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Pulmonary hypertension: the unaddressed global health burden. <i>Lancet Respiratory Medicine</i> , 2018, 6, 577-579.	5.2	28
74	The Effects of Vasodilators in Pulmonary Hypertension. <i>Circulation: Heart Failure</i> , 2009, 2, 145-150.	1.6	27
75	Familial Pulmonary Hypertension in Association with an Abnormal Hemoglobin. <i>Chest</i> , 1991, 99, 1208-1210.	0.4	24
76	Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 2003, 92, 1366-1368.	0.7	23
77	Development of Nonspecific Interstitial Pneumonitis Associated With Long-term Treatment of Primary Pulmonary Hypertension With Prostacyclin. <i>Chest</i> , 1999, 116, 566-569.	0.4	20
78	Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography. <i>American Heart Journal</i> , 1997, 134, 1115-1119.	1.2	19
79	Pulmonary hypertension. <i>Current Problems in Cardiology</i> , 2004, 29, 575-634.	1.1	17
80	What is Pulmonary Arterial Hypertension?. <i>Pulmonary Circulation</i> , 2012, 2, 271-272.	0.8	17
81	The Medical Treatment of Primary Pulmonary Hypertension. <i>Chest</i> , 1994, 105, 17S-20S.	0.4	16
82	Short-term effectiveness of nifedipine in secondary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1993, 71, 1475-1476.	0.7	15
83	Primary pulmonary hypertension. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 135-139.	0.4	15
84	The Role of Thrombosis in Pulmonary Hypertension. <i>Chest</i> , 1993, 103, 660-661.	0.4	11
85	Targeting Pulmonary Vascular Disease To Improve Global Health. <i>Chest</i> , 2010, 137, 1S-5S.	0.4	11
86	Are anticoagulants still indicated in pulmonary arterial hypertension?. <i>Pulmonary Circulation</i> , 2018, 8, 1-5.	0.8	11
87	SEVERE PULMONARY HYPERTENSION: CRITICAL CARE CLINICS. <i>Critical Care Clinics</i> , 2001, 17, 453-467.	1.0	8
88	Serum nifedipine concentrations and response of patients with pulmonary hypertension. <i>American Journal of Cardiology</i> , 1996, 77, 996-999.	0.7	7
89	Lung Transplantation for Pulmonary Hypertension: Patient Selection and Maintenance Therapy While Awaiting Transplantation. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 1998, 10, 135-138.	0.4	7
90	Future of Clinical Trials for Pulmonary Hypertension. <i>Circulation</i> , 2011, 123, 2919-2921.	1.6	7

#	ARTICLE	IF	CITATIONS
91	Prostacyclin and Primary Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1994, 121, 463.	2.0	5
92	How Do We Explain Unexplained Pulmonary Hypertension in the Elderly?. <i>Chest</i> , 2007, 131, 5-6.	0.4	5
93	A New Classification of Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2002, 1, 3-6.	0.1	5
94	The Importance of Sex in Pulmonary Hypertension. <i>Chest</i> , 2012, 141, 4-5.	0.4	3
95	The Pulmonary Hypertension Academic Research Consortium. <i>Pulmonary Circulation</i> , 2013, 3, 203-205.	0.8	3
96	Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation. <i>Transplantation Reviews</i> , 1998, 12, 205-208.	1.2	0
97	Calcium Channel Blockers in the Treatment of Pulmonary Arterial Hypertension. , 2011, , 1447-1450.		0
98	The Cellular Basis of the Pathophysiology and Treatment of Pulmonary Hypertension. , 1996, , 175-180.		0